This 2014 photo made available by the U.S. Centers for Disease Control and Prevention shows a feeding female Anopheles funestus mosquito. The species is a known vector for malaria. The parasitic disease killed more than 620,000 people in 2020 and caused 241 million cases, mainly in children under 5 in Africa.
“The available vaccine doesn't protect enough people,” said Dr. Kassoum Kayentao of the University of Sciences, Techniques and Technologies in Bamako, Mali, who helped lead the study in the villages of Kalifabougou and Torodo. The U.S. government research was published Monday in the New England Journal of Medicine and presented at a medical meeting in Seattle.
Infections were detected by blood test in 20 people who got the higher dose, 39 people who got the lower dose and 86 who got the placebo.Protection might last during the several months of a malaria season. The idea is to someday use it alongside other malaria prevention methods such as malaria pills, mosquito nets and vaccines. Cost is uncertain, but one estimate suggests lab-made antibodies could be given for as little as $5 per child per malaria season.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: KPRC2 - 🏆 80. / 68 Read more »
Source: wrtv - 🏆 598. / 51 Read more »
Source: wjxt4 - 🏆 246. / 63 Read more »